JP5824511B2 - 非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法 - Google Patents

非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法 Download PDF

Info

Publication number
JP5824511B2
JP5824511B2 JP2013509129A JP2013509129A JP5824511B2 JP 5824511 B2 JP5824511 B2 JP 5824511B2 JP 2013509129 A JP2013509129 A JP 2013509129A JP 2013509129 A JP2013509129 A JP 2013509129A JP 5824511 B2 JP5824511 B2 JP 5824511B2
Authority
JP
Japan
Prior art keywords
emulsion
proemulsion
oil
formulation
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013509129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525485A5 (enExample
JP2013525485A (ja
Inventor
喜一郎 鍋田
喜一郎 鍋田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teikoku Pharma USA Inc
Original Assignee
Teikoku Pharma USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teikoku Pharma USA Inc filed Critical Teikoku Pharma USA Inc
Publication of JP2013525485A publication Critical patent/JP2013525485A/ja
Publication of JP2013525485A5 publication Critical patent/JP2013525485A5/ja
Application granted granted Critical
Publication of JP5824511B2 publication Critical patent/JP5824511B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2013509129A 2010-05-03 2011-04-29 非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法 Expired - Fee Related JP5824511B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33070510P 2010-05-03 2010-05-03
US61/330,705 2010-05-03
PCT/US2011/034586 WO2011139899A2 (en) 2010-05-03 2011-04-29 Non-aqueous taxane pro-emulsion formulations and methods of making and using the same

Publications (3)

Publication Number Publication Date
JP2013525485A JP2013525485A (ja) 2013-06-20
JP2013525485A5 JP2013525485A5 (enExample) 2014-10-16
JP5824511B2 true JP5824511B2 (ja) 2015-11-25

Family

ID=44858719

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013509129A Expired - Fee Related JP5824511B2 (ja) 2010-05-03 2011-04-29 非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法

Country Status (22)

Country Link
US (2) US10842770B2 (enExample)
EP (1) EP2566474B1 (enExample)
JP (1) JP5824511B2 (enExample)
KR (1) KR101752944B1 (enExample)
CN (2) CN109745287A (enExample)
AP (1) AP3552A (enExample)
AU (1) AU2011248449B2 (enExample)
BR (1) BR112012028037A2 (enExample)
CA (1) CA2798180A1 (enExample)
CO (1) CO6640232A2 (enExample)
EA (1) EA027666B1 (enExample)
ES (1) ES2652509T3 (enExample)
IL (1) IL222785A0 (enExample)
MX (1) MX341082B (enExample)
MY (1) MY167224A (enExample)
NZ (1) NZ603828A (enExample)
PH (1) PH12012502163A1 (enExample)
SG (2) SG185389A1 (enExample)
TW (2) TW201526889A (enExample)
UA (1) UA109275C2 (enExample)
WO (1) WO2011139899A2 (enExample)
ZA (1) ZA201208229B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5824511B2 (ja) 2010-05-03 2015-11-25 テイコク ファーマ ユーエスエー インコーポレーテッド 非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法
CN108158991A (zh) * 2012-07-19 2018-06-15 富士胶片株式会社 含紫杉烷系活性成分的液体组合物、其制造方法及液体制剂
JO3685B1 (ar) * 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CN104720070A (zh) * 2013-12-20 2015-06-24 财团法人食品工业发展研究所 微乳液预浓缩物和微乳液及其制备方法
TWI531318B (zh) 2013-12-20 2016-05-01 財團法人食品工業發展研究所 微乳液預濃縮物和微乳液暨其製備方法
CN106176599A (zh) * 2015-05-06 2016-12-07 江苏天士力帝益药业有限公司 一种卡巴他赛脂肪乳注射剂及其制备方法
JP6292267B2 (ja) * 2016-09-13 2018-03-14 ニプロ株式会社 ドセタキセル製剤
CN110709105A (zh) * 2017-03-31 2020-01-17 技术防卫株式会社 载有药物的非水系组合物及其制备方法
JP2018115178A (ja) * 2018-03-15 2018-07-26 ニプロ株式会社 ドセタキセル製剤

Family Cites Families (212)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US561330A (en) * 1896-06-02 ljungstrom
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
JPS6328743A (ja) 1986-07-23 1988-02-06 Oi Seisakusho Co Ltd 自動車用シ−トスライド装置
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5407683A (en) 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
JPH04164024A (ja) 1990-10-29 1992-06-09 Sankyo Co Ltd 医薬物質含有自己乳化型脂肪乳剤組成物の製造方法
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
FR2678833B1 (fr) 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
DE4208527A1 (de) 1992-03-17 1993-09-23 Max Planck Gesellschaft Liposomen mit negativer ueberschussladung
FR2691460B1 (fr) 1992-05-21 1994-07-22 Rhone Poulenc Rorer Sa Nouveaux derives du taxane, leur preparation et les compositions qui les contiennent.
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
CA2149150C (en) 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
CA2155947C (en) 1993-02-22 2007-08-21 Mark W. Grinstaff Methods for in vivo delivery of biologics and compositions useful therefor
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
WO1999000113A1 (en) 1997-06-27 1999-01-07 Vivorx Pharmaceuticals, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US20030133955A1 (en) 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
CA2091152C (en) 1993-03-05 2005-05-03 Kirsten Westesen Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
US5785976A (en) 1993-03-05 1998-07-28 Pharmacia & Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US5885486A (en) 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
FR2703049B1 (fr) 1993-03-22 1995-04-21 Rhone Poulenc Rorer Sa Procédé de purification des taxoïdes.
JP3526887B2 (ja) 1993-04-23 2004-05-17 帝國製薬株式会社 消炎鎮痛外用貼付剤
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
DE69431071T2 (de) 1993-12-29 2003-03-20 Matrix Pharma Zusammensetzung für lokale freigabe von zytostatika
US5925669A (en) 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
FR2722191B1 (fr) 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
DE4430593C2 (de) 1994-08-20 1999-01-14 Max Delbrueck Centrum Verfahren zur Herstellung von Liposomal verkapseltem Taxol
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5789000A (en) 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5580899A (en) 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
EP0760237A1 (en) 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US5968972A (en) 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
KR100330373B1 (ko) 1996-05-28 2002-11-07 주식회사한국신약 탁솔을 함유한 주사용 약제 조성물
US5877205A (en) 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6727280B2 (en) 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US6121245A (en) 1997-01-29 2000-09-19 Firshein; Richard N. Method of treating cancer using alkylglycerols in conjunction with chemotherapy
CA2285391A1 (en) 1997-03-27 1998-10-01 Baker Norton Pharmaceuticals, Inc. Methods and compositions for treatment of ovarian cancer
CA2211949A1 (en) 1997-07-21 1999-01-29 David Farley Johnson Nonaqueous compositions for parenteral administration
JP4524367B2 (ja) 1997-07-29 2010-08-18 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 自己乳化性処方形態の酸性親油性化合物用の医薬組成物
DK0999838T3 (da) 1997-07-29 2002-07-08 Upjohn Co Selv-emulgerende formulering for lipofile forbindelser
US6281175B1 (en) 1997-09-23 2001-08-28 Scimed Life Systems, Inc. Medical emulsion for lubrication and delivery of drugs
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US6284268B1 (en) 1997-12-10 2001-09-04 Cyclosporine Therapeutics Limited Pharmaceutical compositions containing an omega-3 fatty acid oil
EP1059941B1 (en) 1998-03-05 2004-05-26 Phares Pharmaceutical Research N.V. Pharmaceutical compositions and their use
IL131217A0 (en) 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
DE69931617T2 (de) * 1998-04-01 2007-05-24 Jagotec Ag Taxan-mikroemulsionen
AU3843999A (en) 1998-05-07 1999-11-23 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
JP2002535242A (ja) 1998-05-20 2002-10-22 ザ リポソーム カンパニー、インコーポレーテッド 新規な粒子状剤型
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6017948A (en) 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
US6071952A (en) 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
KR100602725B1 (ko) 1998-12-11 2006-07-20 파마솔루션스, 인코포레이티드 물에서 불충분하게 용해되는 약제를 위한 자가-유화용조성물
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
AU777528B2 (en) 1999-04-22 2004-10-21 Abraxis Bioscience, Llc Long term administration of pharmacologically active agents
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
EP1479382A1 (en) 1999-06-18 2004-11-24 IVAX Research, Inc. Oral pharmaceutical compositions containing taxanes and methods for treatment employing the same
TW422706B (en) 1999-07-01 2001-02-21 Wang Iz Rung An oil-in-water emulsion type of paclitaxel
GB9920548D0 (en) 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
WO2001021154A2 (en) 1999-09-21 2001-03-29 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
WO2001025223A1 (en) 1999-10-06 2001-04-12 The Research Foundation Of State University Of New York Stabilization of taxane-containing dispersed systems
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6828346B2 (en) 1999-10-25 2004-12-07 Supergen, Inc. Methods for administration of paclitaxel
RU2002113659A (ru) 1999-10-27 2004-01-27 Бейкер Нортон Фармасьютикалз, Инк. (Us) Способ и композиции для перорального введения таксанов больным людям
US7919113B2 (en) 1999-12-30 2011-04-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dispersible concentrate lipospheres for delivery of active agents
PL350075A1 (en) 2000-02-02 2002-11-04 Univ Florida State Res Found Taxane formulations having improved solubility
KR20030019328A (ko) 2000-03-24 2003-03-06 아이박스 리서치 인코포레이티드 탁산-기저 조성물 및 이를 이용한 방법
JP3448006B2 (ja) 2000-03-29 2003-09-16 独立行政法人食品総合研究所 機能性エマルション
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
JP2004511426A (ja) 2000-05-03 2004-04-15 ミュンヘン　バイオテク　アーゲー 活性化血管部位に関連する陽イオン性の診断薬、画像化剤、および治療薬
DE10036871A1 (de) 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
US20020141966A1 (en) 2000-11-16 2002-10-03 Wenbin Dang Compositions for treatment of malignant effusions, and methods of making and using the same
JP2004536026A (ja) * 2000-11-28 2004-12-02 トランスフォーム ファーマシューティカルズ，インコーポレーティッド． パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤
EP1345589B1 (en) 2000-11-29 2007-06-27 Lyotropic Therapeutics, Inc. Solvent systems for pharmaceutical agents
US20030099674A1 (en) * 2001-08-11 2003-05-29 Chen Andrew X. Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
US6815642B2 (en) 2001-12-19 2004-11-09 Delphi Technologies, Inc. Apparatus and method for heating a steering wheel
CA2486909A1 (en) 2002-05-23 2003-12-04 Umd, Inc. Compositions and method for transmucosal drug delivery and cryoprotection
AU2003302721B2 (en) 2002-08-02 2009-10-08 Beyondspring Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
JP4416653B2 (ja) 2002-08-21 2010-02-17 ファルマシア コーポレーション ２つのチャンバーを有するバイアルに収容された注射用医薬懸濁液
US20080220074A1 (en) 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
CA2500908A1 (en) 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
JP2006514698A (ja) 2002-10-30 2006-05-11 スフェリックス， インコーポレイテッド ナノ粒子生物活性物質
US20040122081A1 (en) * 2002-11-08 2004-06-24 Gogate Uday Shankar Pharmaceutical compositions and methods of using taxane derivatives
US6838569B2 (en) 2002-12-16 2005-01-04 Dabur India Limited Process for preparation of paclitaxel trihydrate and docetaxel trihydrate
AU2003303513A1 (en) 2002-12-30 2004-07-29 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
US8703982B2 (en) 2003-03-17 2014-04-22 Phyton Holdings Llc Purification of taxanes
EP1631265A2 (en) 2003-05-30 2006-03-08 Arc Pharmaceuticals, Inc. Use of various agents for inhibiting fibrous adhesions
EP1498120A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
EP1498143A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
US20060292186A1 (en) 2003-08-29 2006-12-28 Novagali Pharma Sa Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
EP1947094A3 (en) 2003-12-12 2009-02-18 Quiral Quimica Do Brasil Process for the preparation of taxane derivatives
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
CA2569003A1 (en) 2004-05-07 2005-12-08 Massachusetts Institute Of Technology Methods and compositions for cancer treatment relating to brca1 brct domain recognition of phosphorylated bach1
US8557861B2 (en) 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
US7446126B2 (en) 2004-10-08 2008-11-04 Indena S.P.A. Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel
WO2006050123A1 (en) 2004-10-29 2006-05-11 Novartis Ag Spontaneously dispersible pharmaceutical compositions
JP4734910B2 (ja) 2004-12-09 2011-07-27 日油株式会社 難水溶性薬剤用可溶化剤組成物
KR20080003322A (ko) 2005-02-24 2008-01-07 엘란 파마 인터내셔널 리미티드 도세탁셀 및 이의 유사체의 나노입자 배합물
ITMI20050614A1 (it) 2005-04-12 2006-10-13 Indena Spa Processo per la purificazione della 10-deacetilbaccatina iii dalla 10-deacetil-2-debenzoil-2-pentenoilbaccatina iii
EP2308467A3 (en) 2005-06-17 2011-06-22 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
CN101291658B (zh) 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
WO2007044950A2 (en) 2005-10-12 2007-04-19 Sicor, Inc. Crystalline forms of docetaxel and processes for their preparation
EA015781B1 (ru) 2005-10-21 2011-12-30 Панацея Биотек Лимитед Композиции для лечения рака
AR057909A1 (es) 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
CZ300305B6 (cs) 2005-12-20 2009-04-15 Heaton, A. S. Farmaceutická kompozice obsahující derivát taxanu se zlepšenou terapeutickou úcinností
CA2634746A1 (en) 2005-12-21 2007-07-05 Tapestry Pharmaceuticals, Inc. Processes for taxane derivatives and intermediates useful therein
US20090156828A1 (en) 2005-12-21 2009-06-18 Tapestry Pharmaceuticals, Inc. Novel Compounds and Methods for Forming Taxanes and Using the Same
KR100995390B1 (ko) 2006-01-02 2010-11-19 주식회사 삼양제넥스 무정형, 무수결정형 또는 수화 결정형 도세탁셀의 제조방법
EP1808173A1 (en) 2006-01-12 2007-07-18 Matthias Dormeyer Use of CNS penetrating anticancer compounds for the treatment of protozan diseases
BRPI0600285C1 (pt) 2006-01-13 2011-10-11 Brz Biotecnologia Ltda compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
CA2639921C (en) 2006-01-23 2014-01-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Microspheres comprising nanocapsules containing a lipophilic drug
BRPI0600194A (pt) 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
CN101023940A (zh) 2006-02-20 2007-08-29 郝守祝 一种紫杉烷类化合物的药用组合物、制备方法及用途
CA2642324C (en) 2006-02-21 2011-03-29 Dabur Pharma Limited Stable pharmaceutical composition of taxanes
US20070264349A1 (en) 2006-03-07 2007-11-15 Novavax, Inc. Nano-structured compositions and methods of making and using the same
KR20080100264A (ko) 2006-03-21 2008-11-14 닥터 레디스 레보러터리즈 리미티드 도세탁셀의 다형체와 그 제조방법
US20090306400A1 (en) 2006-03-27 2009-12-10 Henri John T Convergent process for the synthesis of taxane derivatives.
RU2008142388A (ru) 2006-04-03 2010-05-10 Тева Фармасьютикл Индастриес Лтд. (Il) Микрочастицы лекарственного вещества
AU2007246077A1 (en) 2006-05-03 2007-11-08 I.Q.A., A.S. Pharmaceutical composition containing taxane derivative destined for the preparation of an infusion solution, method of preparation thereof and use thereof
KR100917809B1 (ko) 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
JP2009542608A (ja) 2006-06-29 2009-12-03 アステックス・セラピューティクス・リミテッド 医薬組合せ剤
US20100034749A1 (en) 2006-07-10 2010-02-11 Medigene Ag Use of a Cationic Collodal Preparation for the Diagnosis and Treatment of Ocular Diseases
US8728527B2 (en) 2006-07-24 2014-05-20 Luminus Biosciences, Inc. Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening
WO2008026048A2 (en) 2006-08-31 2008-03-06 Wockhardt Research Centre Stable injectable pharmaceutical compositions of docetaxel
EP2330101A1 (en) 2006-10-20 2011-06-08 Scinopharm Singapore Pte, Ltd. Process for making crystalline docetaxel
US20110002851A1 (en) 2006-11-03 2011-01-06 Medigene Ag Cationic Colloidal Carriers for Delivery of Active Agents to the Blood-Brain Barrier in the Course of Neuroinflammatory Diseases
CN100998560A (zh) * 2006-12-27 2007-07-18 沈阳药科大学 多烯紫杉醇冻干乳剂及其制备方法
EP1946747A1 (en) 2007-01-17 2008-07-23 Sandoz AG Pharmaceutical composition of improved stability containing taxane derivatives
CN101244053B (zh) * 2007-02-16 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 以多西他赛为主组分的新的分散体系
WO2008102374A1 (en) 2007-02-20 2008-08-28 Dabur Pharma Limited Amorphous form of docetaxel
AU2008227852B2 (en) 2007-03-19 2011-02-24 Fresenius Kabi Oncology Ltd. Proliposomal and liposomal compositions
KR100878455B1 (ko) 2007-04-10 2009-01-13 한미약품 주식회사 안정한 무수결정형 도세탁셀 및 이의 제조방법
US20080262078A1 (en) 2007-04-20 2008-10-23 Namdeo Alok B Pharmaceutical Compositions
FR2917088B1 (fr) 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
CN101677987A (zh) 2007-06-22 2010-03-24 赛多斯有限责任公司 不含吐温80的多西他赛的增溶制剂
WO2009006590A2 (en) 2007-07-04 2009-01-08 Dr. Reddy's Laboratories Ltd. Docetaxel process and polymorphs
CN101396354B (zh) 2007-09-30 2010-12-01 江苏恒瑞医药股份有限公司 一种稳定的塔三烷类化合物液体组合物及其制备方法和其应用
WO2009047794A2 (en) * 2007-10-01 2009-04-16 Intas Pharmaceuticals Limited Taxane derivative composition
FR2922107B1 (fr) 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
MX2010003594A (es) 2007-10-23 2010-09-22 Antisoma Res Ltd Formas cristalinas de sal sodica de dmxaa.
US20090130198A1 (en) 2007-11-21 2009-05-21 Innopharmax Inc. Pharmaceutical composition with enhanced bioavailability
PL2231144T3 (pl) 2007-12-24 2014-12-31 Sun Pharma Advanced Res Co Ltd Nanodyspersja
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
CN101525321B (zh) 2008-03-06 2012-03-07 上海希迪制药有限公司 多烯紫杉醇倍半水结晶体及其制备方法
EP2265618A2 (en) 2008-03-14 2010-12-29 Sunesis Pharmaceuticals, Inc. Aurora kinase inhibitors
WO2009121069A2 (en) 2008-03-28 2009-10-01 University Of Massachusetts Compositions and methods for the preparation of nanoemulsions
AU2008354007A1 (en) 2008-04-04 2009-10-08 Robert Rodriguez Lipid-oil-water nanoemulsion delivery system for microtubule-interacting agents
CN102026667B (zh) 2008-04-18 2014-06-25 安吉奥开米公司 紫杉醇、紫杉醇类似物或紫杉醇结合物的药物组合物及相关制备方法和用途
AU2009280803B2 (en) 2008-07-23 2013-10-31 Bharat Serums And Vaccines Ltd. Stable injectable oil-in-water Docetaxel nanoemulsion
ES2344674B1 (es) 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
WO2010023321A1 (en) 2008-09-01 2010-03-04 Stragen Pharma S.A. Liquid formulation containing a taxane derivative
WO2010033771A2 (en) 2008-09-19 2010-03-25 Trustees Of The University Of Pennsylvania Modulators of hsp70/dnak function and methods of use thereof
EP2172193A1 (en) 2008-10-02 2010-04-07 Capsulution Nanoscience AG Improved nanoparticulate compositions of poorly soluble compounds
US20110195030A1 (en) 2008-10-15 2011-08-11 The University Of North Carolina At Chapel Hill Nanoparticle compositions comprising liquid oil cores
US8858912B2 (en) 2008-10-31 2014-10-14 The Invention Science Fund I, Llc Frozen compositions and methods for piercing a substrate
US8731840B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US8603494B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US20100111831A1 (en) 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for surface abrasion with frozen particles
US9050317B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9060926B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US20100111841A1 (en) 2008-10-31 2010-05-06 Searete Llc Compositions and methods for surface abrasion with frozen particles
US8731841B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8545806B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8545857B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8603495B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8849441B2 (en) 2008-10-31 2014-09-30 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US9050251B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US9072799B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8409376B2 (en) 2008-10-31 2013-04-02 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8788211B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US8725420B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
WO2010059916A2 (en) 2008-11-20 2010-05-27 Dr. Reddy's Laboratories Ltd. Preparation of docetaxel
WO2010128504A2 (en) 2009-05-04 2010-11-11 Ben-Gurion University Of The Negev Research And Development Authority Nano-sized particles comprising multi-headed amphiphiles for targeted drug delivery
JP5497336B2 (ja) 2009-05-20 2014-05-21 テクノガード株式会社 薬物を保持した脂肪粒子を含む非水系組成物およびその製造方法
PL388144A1 (pl) 2009-05-29 2010-12-06 Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością Solwaty (2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylopropionianu 4-acetoksy-2α-benzoiloksy -5β,20-epoksy-1,7β,10β-trihydroksy-9-okso-taks-11-en-13α-ylu, sposób ich otrzymywania i zastosowanie
US8778364B2 (en) 2009-06-19 2014-07-15 Sun Pharma Advanced Research Company Ltd. Nanodispersion of a drug and process for its preparation
WO2011025771A1 (en) 2009-08-25 2011-03-03 Biogen Idec Ma Inc. Compositions for delivery of insoluble agents
CN102038635A (zh) 2009-10-23 2011-05-04 天津天士力集团有限公司 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
US8686165B2 (en) 2009-11-04 2014-04-01 Emcure Pharmaceuticals Limited Process for preparation of taxane derivatives
KR101149600B1 (ko) 2009-12-31 2012-05-29 주식회사 삼양제넥스바이오 고순도 무수결정형 도세탁셀 제조방법
JP5824511B2 (ja) 2010-05-03 2015-11-25 テイコク ファーマ ユーエスエー インコーポレーテッド 非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法
WO2012160568A1 (en) 2011-05-23 2012-11-29 Shilpa Medicare Limited Process for preparing docetaxel trihydrate polymorph

Also Published As

Publication number Publication date
TWI511726B (zh) 2015-12-11
KR101752944B1 (ko) 2017-07-03
AP2012006564A0 (en) 2012-12-31
UA109275C2 (uk) 2015-08-10
KR20130092992A (ko) 2013-08-21
EP2566474A2 (en) 2013-03-13
AU2011248449A1 (en) 2012-12-20
EP2566474A4 (en) 2014-06-18
US20110269829A1 (en) 2011-11-03
TW201204350A (en) 2012-02-01
PH12012502163A1 (en) 2017-07-28
TW201526889A (zh) 2015-07-16
EP2566474B1 (en) 2017-11-15
EA027666B1 (ru) 2017-08-31
US20130052241A1 (en) 2013-02-28
WO2011139899A2 (en) 2011-11-10
ES2652509T3 (es) 2018-02-02
MX2012012630A (es) 2013-05-20
CN102970990A (zh) 2013-03-13
AP3552A (en) 2016-01-18
JP2013525485A (ja) 2013-06-20
CN109745287A (zh) 2019-05-14
US10842770B2 (en) 2020-11-24
SG185389A1 (en) 2012-12-28
WO2011139899A3 (en) 2012-04-05
BR112012028037A2 (pt) 2016-08-02
CO6640232A2 (es) 2013-03-22
AU2011248449B2 (en) 2016-09-15
MX341082B (es) 2016-08-08
IL222785A0 (en) 2012-12-31
EA201201453A1 (ru) 2013-04-30
CA2798180A1 (en) 2011-11-10
MY167224A (en) 2018-08-14
NZ603828A (en) 2015-09-25
SG10201503234SA (en) 2015-06-29
ZA201208229B (en) 2013-07-31

Similar Documents

Publication Publication Date Title
US10842770B2 (en) Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
US9763880B2 (en) Non-aqueous taxane formulations and methods of using the same
US8569357B2 (en) Taxane pro-emulsion formulations and methods making and using the same
HK40004915A (en) Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
HK1180591A (en) Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
HK1259184B (en) Non-aqueous taxane nanodispersion formulations and methods of using the same
HK1174850A (en) Taxane pro-emulsion formulations and methods making and using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140826

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20140826

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20140903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141118

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150819

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150911

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151009

R150 Certificate of patent or registration of utility model

Ref document number: 5824511

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees